Icon

INLYTA (nda202324)- (1MG,5MG)

AXITINIB PF PRISM CV
1MG,5MG
Yes No
2037-Jan-12 2017-Jan-27
None None
None No
INLYTA is a kinase inhibitor indicated: • in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). • in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. • as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
0 3 0
Total Other Developers 7
Drugs with Suitability No
1MG ** ** - - -
5MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.